According to the Zhitong Finance App, Tengsheng Pharmaceutical-B (02137.HK) announced interim results for the six months ended June 30, 2026, with other revenue of 19.5 million yuan (RMB, same below), a year-on-year decrease of 30.6%; R&D expenses of 98.3 million yuan, a year-on-year decrease of 16.0%; loss during the period narrowed 101 million yuan, a year-on-year decrease of 32.08%; the basic loss per share was 0.14 yuan.

According to the Zhitong Finance App, Tengsheng Pharmaceutical-B (02137.HK) announced interim results for the six months ended June 30, 2026, with other revenue of 19.5 million yuan (RMB, same below), a year-on-year decrease of 30.6%; R&D expenses of 98.3 million yuan, a year-on-year decrease of 16.0%; loss during the period narrowed 101 million yuan, a year-on-year decrease of 32.08%; the basic loss per share was 0.14 yuan.